NO942228L - Ipsapiron-legemiddeltilberedning - Google Patents

Ipsapiron-legemiddeltilberedning

Info

Publication number
NO942228L
NO942228L NO942228A NO942228A NO942228L NO 942228 L NO942228 L NO 942228L NO 942228 A NO942228 A NO 942228A NO 942228 A NO942228 A NO 942228A NO 942228 L NO942228 L NO 942228L
Authority
NO
Norway
Prior art keywords
hours
release
ipsapirone
drug preparation
ipsaplron
Prior art date
Application number
NO942228A
Other languages
English (en)
Other versions
NO942228D0 (no
Inventor
Peter Serno
Wolfgang Fischer
Roland Rupp
Mark Versavel
Ulrich Tenter
Gerhard Schmidt
Gunter Schollnhammer
Maria Ammen
Shinji Maegata
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO942228D0 publication Critical patent/NO942228D0/no
Publication of NO942228L publication Critical patent/NO942228L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det blir beskrevet Ipsaplron-legemlddeltllberednlnger med midlere frlglvlngshastlghet mellom 80*/5 timer til 8056/13 timer og en inltiell frlgivingshastighet på mindre enn 35* ipsaplron i de første 2 timene av fri- gi vnlngen. Disse tilberedningene har god biotilgjengelighet og lagerstabilltet, og består av dlsfusjonskontrollerte pellets eller erosjonstabletter med definert virke- stoff -frigi ving.
NO942228A 1993-06-15 1994-06-14 Ipsapiron-legemiddeltilberedning NO942228L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4319760A DE4319760A1 (de) 1993-06-15 1993-06-15 Ipsapiron Arzneimittelzubereitung

Publications (2)

Publication Number Publication Date
NO942228D0 NO942228D0 (no) 1994-06-14
NO942228L true NO942228L (no) 1994-12-16

Family

ID=6490360

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942228A NO942228L (no) 1993-06-15 1994-06-14 Ipsapiron-legemiddeltilberedning

Country Status (16)

Country Link
EP (1) EP0629402A1 (no)
JP (1) JPH06345649A (no)
KR (1) KR950000150A (no)
CN (1) CN1099263A (no)
AU (1) AU6345794A (no)
CA (1) CA2125620A1 (no)
CZ (1) CZ146494A3 (no)
DE (1) DE4319760A1 (no)
FI (1) FI942803L (no)
HU (1) HUT70759A (no)
IL (1) IL109993A0 (no)
NO (1) NO942228L (no)
NZ (1) NZ260732A (no)
PL (1) PL303822A1 (no)
SK (1) SK72494A3 (no)
ZA (1) ZA944187B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
KR100437105B1 (ko) * 1998-12-24 2004-06-23 얀센 파마슈티카 엔.브이. 방출 조절형 갈란타민 조성물
WO2004103338A1 (en) * 2003-05-19 2004-12-02 Bioprogress Plc Adhesives and film modifying compositions
JP7536098B2 (ja) * 2020-09-02 2024-08-19 北京華昊中天生物医薬股▲ふん▼有限公司 ウチデロンの経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386440B1 (de) * 1989-02-11 1992-08-05 Bayer Ag Arzneimittel mit kontrollierter Wirkstoffabgabe
DD297767A5 (de) * 1990-03-06 1992-01-23 Bayer Aktiengesellschaft,De Arzneimittel mit kontrollierter wirkstoffabgabe
JPH04360826A (ja) * 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤

Also Published As

Publication number Publication date
FI942803A7 (fi) 1994-12-16
KR950000150A (ko) 1995-01-03
NZ260732A (en) 1996-02-27
ZA944187B (en) 1995-02-08
CA2125620A1 (en) 1994-12-16
CZ146494A3 (en) 1995-01-18
IL109993A0 (en) 1994-10-07
HU9401771D0 (en) 1994-09-28
CN1099263A (zh) 1995-03-01
AU6345794A (en) 1994-12-22
FI942803L (fi) 1994-12-16
JPH06345649A (ja) 1994-12-20
NO942228D0 (no) 1994-06-14
SK72494A3 (en) 1995-04-12
EP0629402A1 (de) 1994-12-21
PL303822A1 (en) 1995-01-09
HUT70759A (en) 1995-10-30
DE4319760A1 (de) 1994-12-22
FI942803A0 (fi) 1994-06-13

Similar Documents

Publication Publication Date Title
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
TR199802034T2 (xx) �apraz ba�lant�l� amylose ve hydroxypropylmethylcellulose baz�nda bir ta��y�c� i�eren kontroll� ��z�l�ml� farmas�tik tablet.
GEP20012442B (en) Irreversible Inhibitors of Tyrosine Kinases
DE69416409D1 (de) Asp-b28-insulinkristalle
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
IL128801A (en) Pharmaceutical composition comprising a substance inhibiting no synthase
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
AU692430B2 (en) Aqueous pharmaceutical preparations of G-CSF with a long shelf life
WO1994012165A3 (en) Enzyme inhibitors
CA2030838A1 (en) Preparations containing l-carnitine
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
EP1452172A3 (en) Multiple unit pharmaceutical preparation
CA2304808A1 (en) Liquid interferon-.beta. formulations
ATE397665T1 (de) Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
EP0147146A3 (en) Enhancement of transdermal drug delivery
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
AU2670495A (en) Ifn-beta liquid formulations
AU4949993A (en) Drugs containing diphosphonic acids and salts thereof
AU687623B2 (en) Cell Adhesion peptides for use in modifying mutual adhesion among eukaryotic cells
NO994898D0 (no) Cytomodulering av lipofile peptider for aa modulere immunsystemaktivitet og inhibere inflammasjon
FR2749514B1 (fr) Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
WO1996015234A3 (de) Lipidspaltendes enzym
HU9300174D0 (en) 2'-desoxi-oligonucleotides containing 5-alkyl,5-(1-alkenyl)- and 5-(1-alenyl)-pyrimidine bases being applicables for medical purposes
FISCHER‐STENGER et al. Separation of soluble amoebicidal and tumoricidal activity of activated macrophages